Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Severe Hypoxemic COVID-19
NCT04822818Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Time to recovery for a category 0 to 5 on the WHO Progression scale at 28 days. Started Apr 2021; status: completed.
02
Drugs
bevacizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04822818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04822818.